Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 50,382

Document Document Title
WO/2018/129647A1
A purified oligosaccharide compound having antithrombotic activity or a mixture of a homologous compound thereof and a pharmaceutically acceptable salt thereof, a preparation method for the mixture, a pharmaceutical composition containin...  
WO/2018/131724A1
Provided are a neutrophil activation regulator and a therapeutic agent against diseases caused by neutrophil activation. A thrombin-like enzyme is used as an active ingredient of the neutrophil activation regulator and the therapeutic ag...  
WO/2018/131717A1
A dough which has excellent formability even while containing a polymer material having ion adsorption capacity or ion exchange capacity, a baked confectionery which is the baked product of said dough, a pharmaceutical composition formed...  
WO/2018/130519A1
The present invention concerns medium molecular weight heparin (MMWH 10.5 kD) for prevention and treatment of venous thromboembolism in malignant disease.  
WO/2018/130840A1
The invention relates to the treatment and/or prevention of cardiovascular disease, for example thromboembolic conditions, such as atherothrombotic disease. In particularly, the invention relates to an arginine methylation inhibitor ('Ar...  
WO/2018/131551A1
In order to provide a novel gene therapy means against hemophilia, the present invention provides a recombinant adeno-associated virus (rAAV) vector for treating disorders related to blood clotting. This virus vector includes a virus gen...  
WO/2018/131716A1
A dough which yields a baked confectionery that disintegrates favorably in the mouth and which contains a polymer material having an ion adsorption capacity or ion exchange capacity, a baked confectionery which is the baked product of sa...  
WO/2018/127762A1
The present invention relates to the novel key intermediate, 4-{4-[(5S)-(Aminomethyl)-2- oxo-l,3-oxazolidin-3-yl]-phenyl}-morpholin-3-one perchlorate, in the synthesis of rivaroxaban. The invention further relates to the crystalline form...  
WO/2018/128689A1
Adeno-associated liquid and lyophilized pharmaceutical compositions are provided herein. In exemplary aspects, the pharmaceutical compositions comprise about 5 mM to about 25 mM L-histidine, about 0 mM to about 150 mM sodium chloride, ab...  
WO/2018/126322A1
An apparatus, method, and use for ultrasound mediated microbubble delivery of pharmaceutical compositions to pulmonary tissue are provided. The pulmonary ultrasound apparatus includes an ultrasound signal generator for generating ultraso...  
WO/2018/122409A1
Compositions including an fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to inflammation and conditions...  
WO/2018/124216A1
The present invention pertains to a method for producing a lipid-containing extract substantially free of chlorophylls, the method including a step for obtaining a lipid-containing extract from one or more raw materials selected from the...  
WO/2018/122407A1
Compositions including a fatty acid, such as an odd chain fatty acid or a very long even chain fatty acid, and salts and derivatives thereof, and methods for treatment and prophylaxis of conditions related to anemic conditions, are provi...  
WO/2018/124067A1
The present application provides: a radiation damage protective agent characterized by containing, as an active ingredient, hydrogen gas for treating or alleviating radiation damage suffered by a human patient who has experienced radiati...  
WO/2018/122419A1
The invention relates to the compound of general formula (I) as novel inhibitors of transglutaminases, to methods for producing the inventive compounds, to pharmaceutical compositions containing said inventive compounds and to their use ...  
WO/2018/120777A1
Provided are a rivaroxaban self-emulsifying preparation and a preparation method therefor, wherein the preparation comprises by mass percentage, 1 to 13% of rivaroxaban, 5 to 50% of oil phase, 20 to 70% of emulsifier, 0 - 50% of the coem...  
WO/2018/116255A1
The present disclosure relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI ("Factor XIa"), and pharmaceutical compositions and methods of treatment comprising the same.  
WO/2018/118205A1
The present invention is a malleable controlled release anesthetic combined with a hemostatic for packing in body cavity such as dental extraction cavity, a wound cavity or a surgical cavity.  
WO/2018/113094A1
Disclosed is the use of a fullerene structure in the preparation of a drug for treating diabetes and complications thereof. The fullerene structure comprises at least one effective ingredient selected from the group consisting of an oil-...  
WO/2018/115953A1
Compositions, including albumin compositions, which inhibit or reduce epithelial- mesenchymal transition (EMT) are described. In embodiments, such compositions comprise albumin and either i) no pro-EMT agent or a low concentration of pro...  
WO/2018/113788A1
Provided is a recombinant single-chain human FVIII-Fc fusion protein, wherein the FVIII is a B-domain deleted human FVIII; the Fc is derived from the human IgG1 comprising a N297G mutation; two CH2-CH3 domains are joined into a single ch...  
WO/2018/118979A1
The present disclosure relates to the use of hepcidin in therapeutic methods for the treatment of various conditions in which decreasing serum iron concentration may be beneficial.  
WO/2018/115800A1
The invention relates to a pharmaceutical composition comprising between 10 and 30 g/L fibrinogen, between 10 and 300 mM arginine, and between 10 and 300 mM glutamate. In addition, the composition has a pH of between 6 and 8.  
WO/2018/113273A1
A pharmaceutical composition comprising carbetocin, comprising (percent by weight): 0.5%-7% of carbetocin, 1%-10% of a water-soluble matrix material, 0.5%-5% of an amino acid anionic surfactant, 0.1%-5% of a humectant, and the balance of...  
WO/2018/117143A1
Provided is a chromatographic method for collecting blood coagulation factor VII and/or activated blood coagulation factor VII from a plasma-derived fraction with high yield. According to the method of the present application, it becomes...  
WO/2018/112627A1
There is provided herein a new use of a NOD2 agonist for treating monocytopenia. Also described herein is the use of a NOD2 agonist for the conversion of inflammatory Ly6Clow monocytes to patrolling Ly6Clow monocytes. More particularly, ...  
WO/2018/116267A2
The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition compri...  
WO/2018/116287A1
Provided are compositions comprising an anion exchanger and a calcium salt for use as a medicament for inducing hemostasis at a site of bleeding; and methods of preparation thereof.  
WO/2018/109228A1
Subject matter of the present invention is an anti-Adrenomedullin (ADM) antibody or an anti-Adrenomedullin antibody fragment or an anti-ADM non-lg scaffold for use in intervention and therapy of congestion in a patient in need thereof.  
WO/2018/108101A1
The present invention relates to new crystal forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acet ic acid, and a preparation method therefor and uses thereof. A crystal form CS1, a crystal form CS2 and a crystal form CS3...  
WO/2018/107241A1
Treatment of a disease of iron metabolism including the step of administering a peptide effective for inhibiting the binding of hepcidin to α2- macroglobulin, to an individual requiring said treatment.  
WO/2018/107698A1
A method for preventing and treating tissue and organ fibrosis, comprising administering an effective amount of plasminogen to a subject.  
WO/2018/107693A1
A method for preventing and treating systemic sclerosis, comprising administering an effective amount of plasminogen to a subject.  
WO/2018/106742A1
Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.  
WO/2018/103600A1
Provided are a substituted heteroaryl amide compound and a composition comprising same and the use thereof. Disclosed are a heteroaryl amide compound as represented by formula (I), a crystal form, a pharmaceutically acceptable salt, a pr...  
WO/2018/102760A1
The present disclosure provides methods inducing immune tolerance in a human, comprising administering to the human an effective amount of a composition or a chimeric protein comprising a clotting factor and an Fc region.  
WO/2018/101373A1
Provided is an orally disintegrating tablet containing edoxaban, a pharmacologically acceptable salt thereof, or a solvate thereof. The orally disintegrating tablet contains: (A) edoxaban, a pharmacologically acceptable salt thereof, or ...  
WO/2018/102743A1
The present disclosure provides methods treating reversible hemophilic arthropathy of a joint in a human having hemophilia comprising administering to the human an effective amount of a chimeric protein or composition comprising a clotti...  
WO/2018/097254A1
The present invention relates to a novel production method of a triazolopyridine compound or a salt thereof, which has PHD inhibitory activity and is useful for the treatment or prophylaxis of diseases associated with decrease in the EPO...  
WO/2018/094640A1
Disclosed are applications of herbacetin or of a herbacetin composition in preparing a medicament for preventing and treating cardiovascular and cerebrovascular diseases. Experiments show that herbacetin provides the effects of protectin...  
WO/2018/098296A1
Provided herein are compounds of formula (II), pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDACl and/ or HDAC2 activity.  
WO/2018/094126A1
The present disclosure is directed to methods of selecting for modified stem cells in vivo. The present disclosure is also directed to a 6TG dosing schedule. The present disclosure is also directed to an oral formulation comprising 6TG.  
WO/2018/090358A1
Applications of pinocembrin in preparing a medicament for treating cerebral hemorrhage. Cerebral hemorrhage comprises transformative hemorrhage after the onset of cerebral embolism and induced by factors such as a thrombolytic medicament...  
WO/2018/093716A1
The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fi...  
WO/2018/086540A1
Provided are a Haemadipsa sylvestris antithrombotic peptide sylvestin and the use thereof, falling within the technical field of biomedicine. The Haemadipsa sylvestris antithrombotic peptide sylvestin can inhibit FXIIa and kallikrein, ha...  
WO/2018/087271A1
The invention pertains to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment or prophylaxis of a blood coagulation disorder, said treatment or prophylaxis comprising administering the re...  
WO/2018/085932A1
The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions comprising these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provide...  
WO/2018/087267A1
The invention pertains to a polypeptide comprising a truncated von Willebrand Factor (VWF) and a half-life extending moiety, for use in the treatment of a blood coagulation disorder, said treatment comprising administering the polypeptid...  
WO/2018/087677A1
The disclosure provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein: (I). Also provided are methods of making the compounds of Formula (I) and their methods of use.  
WO/2018/083645A1
The present invention relates to the treatment or prevention of P-selectin mediated disorders, and to anti-P-selectin antibodies or binding fragments thereof, for use in the treatment or prevention of such disorders. In particular, the i...  

Matches 1 - 50 out of 50,382